Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers
Christian D. Sadik(University of Lübeck), Patrick Terheyden(University Hospital Schleswig-Holstein), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Daniela Göppner(Universitätsklinikum Gießen und Marburg), Maria Isabel Fleischer(Johannes Gutenberg University Mainz), Friedegund Meier(National Center for Tumor Diseases), Lydia Reinhardt(Technische Universität Dresden), Carmen Loquai(Johannes Gutenberg University Mainz), Ewan A. Langan(University of Manchester), Detlef Zillikens(University of Lübeck), Rudolf Herbst(Helios Klinikum Erfurt)
Cited by 43
Related Papers
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
|New England Journal of Medicine|2017|1.4k